Overview
Tesamorelin is included in this independent research library to separate what has been demonstrated from what remains theoretical. The evidence, regulatory status and terminology vary substantially by compound, so claims should be read in the context of the cited literature.
Tesamorelin suggested dosing guide
A concise reference to the dosing ranges most often used in approved labeling, clinical research, or published research discussions. Evidence strength is shown so established dosing is not confused with experimental protocol.
Titration and protocol notes
Current and legacy FDA formulations use different labeled doses and are not interchangeable.
Annotated dosage protocol
Each row explains what the dosage represents. Read it with the evidence badge above: labeled doses, clinical-trial doses, and commonly discussed research amounts do not carry equal clinical weight.
| Phase | Dose | Schedule | What this dosage means |
|---|---|---|---|
| Starting phase | 1.4–2 mg | Once daily | The entry dose or lowest studied range, used before any protocol-directed increase. |
| Treatment range | 1.4–2 mg | Consistent time each day | The range used after initiation. The applicable dose depends on the labeled indication or study design. |
| Duration / reassessment | Response is reassessed periodically | Reassess before continuing | Current and legacy FDA formulations use different labeled doses and are not interchangeable. Dose changes should never be inferred from vial size or convenient syringe units. |
Tesamorelin reconstitution example
This worked example uses a 10 mg vial, 2 mL of diluent, and a 2,000 mcg reference amount.
Syringe units assume a U-100 syringe. Always verify the vial label, syringe type, formulation, and arithmetic independently.
Safety, handling, and storage
- Suggested ranges are educational summaries, not individualized prescriptions.
- FDA-labeled regimens apply only to the approved product, indication, and delivery system.
- For experimental compounds, human safety, purity, and effective dosing may be unknown.
- Follow product-specific sterility, storage, and beyond-use instructions; do not use damaged or contaminated material.
Tesamorelin calculator
Enter your laboratory values to calculate concentration, draw volume, syringe units, and portions per vial.
Deterministic arithmetic for laboratory documentation only. This tool does not select a dose, provide a protocol, or replace qualified medical or laboratory guidance.
Mechanism and research rationale
Binds the GHRH receptor and stimulates pulsatile pituitary growth-hormone release, which can increase downstream IGF-1 signaling.
Growth-hormone axis
Body composition
Visceral adipose tissue
Key facts
- Evidence tier: FDA-approved drug evidence.
- Research status and regulatory status are not interchangeable.
- This page is an educational reference and does not provide personal medical instructions.
What to keep in mind
References and evidence indexes
Looking for Tesamorelin?
View the corresponding Tesamorelin research product, specifications, and available documentation from Novatherix Laboratories.
View at Novatherix →External catalog link. For qualified laboratory and research use only.